Colombia's National Institute for Drug and Food Surveillance (INVIMA) approves administration of Moderna's COVID-19 vaccine for people ages 12 to 17


Colombia's National Institute of Drug and Food Surveillance (INVIMA) approved the request to modify the Emergency Use Authorization for the Moderna COVID-19 vaccine to include its use in people over 12 years of age, to be administered intramuscularly in a series of 2 doses (0.5 ml each).

The authorization was based on safety data gathered in the ongoing phase 2-3 randomized, placebo-controlled clinical trial being conducted in the United States, involving 3,726 individuals ages 12 to 17, in which the safety, immunogenicity, and efficacy of the vaccine were evaluated. 




Ali K, Berman G, Zhou H et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med. doi:


  • Share: